📰 Planegg News
Page 37 - Planegg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planegg. Real-time updates on events, politics, business and more.
March 15, 2022
National Comprehensive Cancer Network® Updates Designation of Monjuvi® to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas BOSTON,... | March 15, 2022
March 13, 2022
Zacks Investment Research upgraded shares of MorphoSys (NASDAQ:MOR – Get Rating) from a sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, […]
March 11, 2022
DGAP-News: MorphoSys AG / Key word(s): Annual Results10.03.2022 / 22:03 The issuer is solely responsible for the content of this announcement.Conference Call AlertPlanegg/Munich, Germany, March 10, 2022Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022MorphoSys AG (FSE: MOR; NASDAQ: MO...
March 11, 2022
The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.
March 11, 2022
MorphoSys is cutting the drug discovery and R&D work of Constellation Pharmaceuticals, a company it acquired lats year in a $1.7 billion deal. This consolidation of research operations will result in non-cash impairment charge on Constellation’s goodwill.
March 10, 2022
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) announces
March 10, 2022
(PLX AI) - MorphoSys AG reports non-cash impairment charge of € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021.•
March 10, 2022
Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQ:MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET
February 18, 2022
DGAP Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securiti...
January 24, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 24, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report, ranking